Table 42.
ESBL‐ and AmpC‐phenotypes and genotypes in Salmonella spp. isolates from humans by serovar, 2015 (8 MSs and Norway)
| Serovar | Tested for CTX & CAZ | Res to CTX & CAZ | Phenotype | Genotype | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ESBL | AmpC | AmpC + ESBL | Atypical phenotype | ||||||||
| N | N | N | % | N | % | N | % | N | % | ||
| Chester | 104 | 2 | 0.0 | 2 | 1.9 | DHA‐1 | |||||
| Choleraesuis | 5 | 1 | 1 | 20.0 | |||||||
| Enteritidis | 1,727 | 3 | 1 | 0.1 | 1 | 0.1 | |||||
| Group B | 45 | 2 | 1 | 2.2 | 1 | 2.2 | TEM | ||||
| Haifa | 4 | 1 | 1 | 25.0 | SHV‐12 | ||||||
| Heidelberg | 7 | 2 | 1 | 14.3 | 1 | 14.3 | CTX‐M‐15; CMY‐2 | ||||
| Infantis | 155 | 11 | 9 | 5.8 | CTX‐M‐2 & CTX‐M‐9 (2); CTX‐M‐9 (1) | ||||||
| Kentucky | 145 | 2 | 2 | 1.4 | TEM‐15; CTX‐M‐14 | ||||||
| Monophasic Typhimurium 1,4,[5],12:i:‐ | 1,043 | 8 | 6 | 0.6 | 1 | 0.1 | SHV‐12; CTX‐M‐9 (2); CMY‐2 | ||||
| Newport | 51 | 1 | 1 | 2.0 | CTX‐M‐15 | ||||||
| Poona | 13 | 1 | 1 | 7.7 | |||||||
| Saintpaul | 16 | 1 | 1 | 6.3 | |||||||
| Stanley | 248 | 2 | 1 | 0.4 | 1 | 0.4 | CMY‐2 | ||||
| Thompson | 39 | 1 | 1 | 2.6 | CTX‐M‐65 | ||||||
| Typhimurium | 862 | 2 | 3 | 0.3 | 1 | 0.1 | 3 | 0.3 | TEM & CTX‐M‐1 | ||
| Virchow | 40 | 1 | 1 | 2.5 | SHV | ||||||
ESBL: extended‐spectrum beta‐lactamase; N: isolates with this phenotype; %: percentage of isolates with this phenotype from the total tested; CTX: cefotaxime; CAZ: ceftazidime; MSs: Member States.